Ultrahypofractionated Adjuvant Breast Radiation Therapy (± Boost) and Virtual Consultations: Patient Perspectives at 1 Year.

ABSTRACT:

Purpose

In March 2020, a 1-week ultrahypofractionated adjuvant breast radiation therapy schedule, 26 Gy in 5 fractions, and telehealth were adopted to reduce the risk of COVID-19 for staff and patients. This study describes real-world 1-year late toxicity for ultrahypofractionation (including a sequential boost) and patient perspectives on this new schedule and telehealth workflows.

Methods and materials

Consecutive patients were enrolled between March and August 2020. Patient-reported outcome measures, including the presence of breast pain, swelling, firmness, and others, were recorded using the European Organisation for research and treatment of cancer quality of life questionairre (EORTC QLQ) BR45 at baseline, 3 months, 6 months, and 1 year. Virtual teleconferencing witho

SUBMITTER: Nicholson JT 

PROVIDER: S-EPMC11647082 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature